Lily Rosenfield is a Research Analyst for AgencyIQ focused on evaluating qualitative and quantitative data for life sciences companies as well as key regulatory issues related to generic drug products, over-the-counter drugs and dietary supplements.  

Prior to joining AgencyIQ, Lily worked as a Senior Consultant at Booz Allen Hamilton, and as a researcher for the Advisory Board Company (now part of Optum). Her expertise spans multiple areas of health policy, and she has worked closely with healthcare providers, life sciences companies and government agencies. She received her B.A. in Environmental Science from George Washington University in Washington, D.C., where she still resides today.